Biological
EXG102-031
EXG102-031 is a biological therapy with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
-
Type
BIOLOGICAL
Molecule
-
Registry-listed formulations
This catalogue entry has no confirmed scientific concept.
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
0 source entries across 0 studies. This list may not include all unresolved or historical entries.
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Phase 1/2
1
50%
Phase 1
1
50%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 1/2Combined phases
1(50.0%)
Highest Phase Reached
Phase 1/2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Other(1)
Detailed Status
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 1/2
Trials by Phase
Phase 11 (50.0%)
Phase 1/21 (50.0%)
Trials by Status
completed150%
unknown150%
Recent Activity
Clinical Trials (2)
Showing 2 of 2 trials
NCT05903794Phase 1
A Study of EXG102-031 in Patients With wAMD (Everest)
NCT06183814Phase 1/2
A Study of EXG102-031 in Participants With wAMD
All 2 trials loaded
Drug Details
- Intervention Type
- Biological
- Total Trials
- 2